Eco Animal Health Gp - ECOVAXXIN® MG favourable USDA safety assessment

ECO Animal Health

11/03/2026 07:00

RNS Number : 1219W

Eco Animal Health Group PLC

11 March 2026

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

 ECOVAXXIN® MG receives favourable USDA safety assessment

Assessment represents a significant milestone towards US marketing authorisation

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that the United States Department of Agriculture (USDA) has delivered a favourable safety assessment of ECOVAXXIN® MG, the Company's live poultry vaccine targeting Mycoplasma gallisepticum.

 

The USDA's review and acceptance of the Company's ECOVAXXIN® MG safety data represents an important step towards securing marketing authorisation for the vaccine in the United States. The comprehensive risk assessment confirms that ECO meets the USDA's rigorous safety standards, with final regulatory submission for ECOVAXXIN® MG currently anticipated in late 2027.

 

As part of the US registration requirements, ECOVAXXIN® MG was demonstrated to be safe not only for the target species (chickens) but also for non‑target avian species including turkeys and quails. Importantly, the strain did not revert or increase in virulence after passage through chickens, confirming its stability.

 

Mycoplasma gallisepticum is a bacterial pathogen responsible for chronic respiratory disease in chickens and infectious sinusitis in turkeys. The live strain of the bacteria used for ECOVAXXIN® MG is a naturally attenuated isolate shown to be safe for young chicks.

 

David Hallas, Chief Executive Officer of ECO Animal Health, said: "ECO is building a robust product portfolio to provide the poultry industry with safe and effective new vaccines against Mycoplasma infection. ECOVAXXIN® MS represented the Company's first step toward expanding its range of innovative vaccines across priority markets, with commercial launch expected later in 2026.

 

"ECOVAXXIN® MG's strong safety profile builds further positive momentum in our R&D pipeline. The favourable risk assessment underlines that the product meets the USDA's high safety benchmarks and represents a significant milestone towards US marketing authorisation."

 

-Ends-

 

Contacts

 

ECO Animal Health Group plc
David Hallas (Chief Executive Officer)
Christopher Wilks (Chief Financial Officer)
020 8447 8899
ICR Healthcare (Financial PR)
Mary-Jane Elliott
Jessica Hodgson
020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker)
Philip Davies
Samed Ethemi
020 7496 3000
Panmure Liberum (Joint Broker)
Emma Earl
Will Goode
Mark Rogers
Rupert Dearden
020 3100 2000
Equity Development
Hannah Crowe
Matt Evans
020 7065 2692



About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

 

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

 

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

 

Click here for more information: https://ecoanimalhealth.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
MSCZZGMFRGFGVZM